Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oral contraceptive usage among healthcare workers and its impact on COVID-19 booster vaccination immunogenicity.

NPJ vaccines·2026
Same author

Left ventricular non-compaction in heart failure: contemporary perspective on diagnostic challenges and treatment opportunities.

Heart failure reviews·2026
Same author

DIGIT-HF: Results From the Win Ratio Analyses.

Circulation. Heart failure·2026
Same author

Digitoxin in heart failure with reduced ejection fraction according to atrial fibrillation status: the DIGIT-HF trial.

European heart journal·2026
Same author

A novel signal distribution-based approach to characterize atrial cardiomyopathy.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026
Same author

Cell cycle dynamics regulate H3K27 and H3K9 histone modifications in Drosophila.

PLoS biology·2026

Related Experiment Videos

Dysnatraemia in heart failure.

Nikolas Deubner1, Dominik Berliner, Anna Frey

  • 1Department of Internal Medicine I-Cardiology, University Hospital Würzburg, Germany.

European Journal of Heart Failure
|July 24, 2012
PubMed
Summary

Both low and high serum sodium levels (dysnatremia) significantly increase mortality risk in heart failure patients, regardless of ejection fraction. Optimal prognosis is linked to high-normal sodium levels (140-145 mmol/L).

Related Experiment Videos

Area of Science:

  • Cardiology
  • Nephrology
  • Internal Medicine

Background:

  • Hyponatremia is a known prognostic marker in heart failure with reduced ejection fraction (HFrEF).
  • Prognostic implications of dysnatremia in heart failure with preserved ejection fraction (HFpEF) and hypernatremia remain unclear.
  • Serum sodium cut-off levels for prognosis in heart failure are not well-defined.

Purpose of the Study:

  • To investigate correlates of dysnatremia in heart failure patients.
  • To estimate the differential prognostic relevance of dysnatremia in HFrEF and HFpEF.
  • To systematically evaluate the prognostic value of hypernatremia in heart failure.

Main Methods:

  • Analysis of 1000 heart failure patients from the Würzburg Interdisciplinary Network for Heart Failure registry.
  • Utilized non-linear models with restricted cubic splines and Cox proportional hazard regression.
  • Median follow-up of 5.1 years for survivors.

Main Results:

  • Dysnatremia correlates included guideline-recommended heart failure medications, renal function indicators, and inverse associations with cardiac risk factors.
  • Both hyponatremia (HR 2.10) and hypernatremia (HR 1.91) were significantly associated with increased mortality.
  • A U-shaped association between serum sodium and mortality risk was observed, with the best prognosis at 140-145 mmol/L.

Conclusions:

  • Both hypo- and hypernatremia indicate a significantly worse prognosis in heart failure, irrespective of LVEF.
  • Serum sodium levels within the reference range provide differential prognostic information.
  • Levels of 135-139 mmol/L are associated with increased mortality risk in heart failure.